Solara Active Pharma Sciences Limited (SOLARA.BO)
INR 509.6
(3.02%)
INR 509.6
(3.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 861.2 Million INR | -79.14% |
| 2022 | 6.54 Billion INR | 6.6% |
| 2021 | 6.14 Billion INR | -23.78% |
| 2020 | 8.06 Billion INR | 28.59% |
| 2019 | 6.26 Billion INR | 8.97% |
| 2018 | 5.75 Billion INR | 681.37% |
| 2017 | 736.27 Million INR | -83.21% |
| 2016 | 4.38 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 818.3 Million INR | 40.63% |
| 2024 Q2 | 1.75 Billion INR | 18.55% |
| 2023 Q4 | 581.9 Million INR | 75.22% |
| 2023 Q1 | 1.6 Billion INR | -14.81% |
| 2023 Q2 | 1.87 Billion INR | 17.08% |
| 2023 FY | 1.36 Billion INR | -79.14% |
| 2023 Q3 | 332.1 Million INR | -82.31% |
| 2022 Q2 | 1.48 Billion INR | 10.8% |
| 2022 Q4 | 1.88 Billion INR | 2.63% |
| 2022 FY | 6.54 Billion INR | 6.6% |
| 2022 Q1 | 1.34 Billion INR | 199.0% |
| 2022 Q3 | 1.83 Billion INR | 23.08% |
| 2021 Q4 | 449.7 Million INR | -2.62% |
| 2021 FY | 6.14 Billion INR | -23.78% |
| 2021 Q3 | 461.8 Million INR | -78.47% |
| 2021 Q2 | 2.14 Billion INR | -5.55% |
| 2021 Q1 | 2.27 Billion INR | 56.62% |
| 2020 FY | 8.06 Billion INR | 28.59% |
| 2020 Q2 | 2.23 Billion INR | 12.41% |
| 2020 Q1 | 1.98 Billion INR | 178.11% |
| 2020 Q3 | 2.39 Billion INR | 6.98% |
| 2020 Q4 | 1.45 Billion INR | -39.33% |
| 2019 Q4 | 714.6 Million INR | -63.44% |
| 2019 FY | 6.26 Billion INR | 8.97% |
| 2019 Q3 | 1.95 Billion INR | 7.7% |
| 2019 Q2 | 1.81 Billion INR | 1.71% |
| 2019 Q1 | 1.78 Billion INR | 130.63% |
| 2018 Q4 | 773.8 Million INR | -57.17% |
| 2018 FY | 5.75 Billion INR | 681.37% |
| 2018 Q1 | 1.5 Billion INR | 1.19% |
| 2018 Q2 | 1.66 Billion INR | 10.13% |
| 2018 Q3 | 1.8 Billion INR | 8.67% |
| 2017 Q4 | 1.49 Billion INR | 0.0% |
| 2017 Q2 | 156.71 Million INR | -87.7% |
| 2017 Q1 | 1.27 Billion INR | 0.0% |
| 2017 FY | 736.27 Million INR | -83.21% |
| 2016 FY | 4.38 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 96.784% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.443% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 93.073% |
| Granules India Limited | 16.79 Billion INR | 94.874% |
| Indoco Remedies Limited | 6.04 Billion INR | 85.745% |
| Achyut Healthcare Limited | 4.86 Million INR | -17616.519% |
| Ajanta Pharma Limited | 21.06 Billion INR | 95.912% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.353% |
| Alpa Laboratories Limited | 188.89 Million INR | -355.915% |
| Brooks Laboratories Limited | 65.62 Million INR | -1212.405% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 86.16% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 41.487% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 76.696% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.474% |
| Eris Lifesciences Limited | 10.42 Billion INR | 91.741% |
| FDC Limited | 8.33 Billion INR | 89.667% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.758% |
| Gufic Biosciences Limited | 4.16 Billion INR | 79.336% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 86.097% |
| Ipca Laboratories Limited | 29.8 Billion INR | 97.111% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -31.966% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -346.85% |
| Lasa Supergenerics Limited | 121.02 Million INR | -611.559% |
| Laurus Labs Limited | 24.62 Billion INR | 96.502% |
| Lupin Limited | 123.71 Billion INR | 99.304% |
| Mankind Pharma Limited | 44.52 Billion INR | 98.066% |
| Medicamen Biotech Limited | 495.49 Million INR | -73.806% |
| Medico Remedies Limited | 262.14 Million INR | -228.522% |
| Megasoft Limited | 342.07 Million INR | -151.761% |
| NATCO Pharma Limited | 25.73 Billion INR | 96.654% |
| Piramal Pharma Limited | 24.47 Billion INR | 96.481% |
| RPG Life Sciences Limited | 2.48 Billion INR | 65.316% |
| Sigachi Industries Limited | 2 Billion INR | 56.989% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.667% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 79.114% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 8.616% |
| Unichem Laboratories Limited | 4.86 Billion INR | 82.298% |
| Wanbury Limited | 1.73 Billion INR | 50.238% |
| Windlas Biotech Limited | 1.33 Billion INR | 35.674% |
| ZIM Laboratories Limited | 1.26 Billion INR | 32.022% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.312% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 242.96% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.345% |
| Hester Biosciences Limited | 1.27 Billion INR | 32.383% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 85.104% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 44.672% |
| Bal Pharma Limited | 770.19 Million INR | -11.816% |
| Strides Pharma Science Limited | 14.38 Billion INR | 94.015% |
| Venus Remedies Limited | 2.18 Billion INR | 60.542% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 85.232% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 71.023% |
| Shilpa Medicare Limited | 3.54 Billion INR | 75.719% |
| Aarti Drugs Limited | 8.31 Billion INR | 89.644% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 81.2% |
| Suven Life Sciences Limited | -200.79 Million INR | 528.891% |
| Ind-Swift Limited | 2.17 Billion INR | 60.36% |
| Valiant Laboratories Limited | -60.66 Million INR | 1519.623% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 96.206% |
| Themis Medicare Limited | 1.5 Billion INR | 42.736% |
| Hikal Limited | 3.14 Billion INR | 72.6% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.158% |
| Sequent Scientific Limited | 2.97 Billion INR | 71.088% |
| Novartis India Limited | 1.32 Billion INR | 35.097% |
| Wockhardt Limited | 16.24 Billion INR | 94.697% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 95.616% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -5806.843% |
| Neuland Laboratories Limited | 8.24 Billion INR | 89.558% |
| Morepen Laboratories Limited | 6.16 Billion INR | 86.022% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -38.796% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -22.398% |